Insulin is an anabolic hormone that elicits metabolic effects throughout the body. In the pancreas, exocrine tissue known as the islets of Langerhans contain beta cells. Beta cells are responsible for insulin synthesis. By monitoring levels of glucose, amino acids, keto acids, and fatty acids circulating within the plasma, beta cells regulate the production of insulin accordingly. Insulin’s overall role is to control energy conservation and utilization during feeding and fasting states.
Key Metabolic Process Definitions
Gluconeogenesis: Synthesis of glucose using non-carbohydrate precursors
Glycolysis: Degradation of glucose into pyruvic acid and energy for cell metabolism
Glycogenesis: Synthesis of glycogen from glucose
Glycogenolysis: Degradation of glycogen into glucose
Lipogenesis: Conversion of acetyl-CoA into fatty acids and subsequent triglyceride synthesis
Lipolysis: Degradation of lipids and triglycerides into free fatty acids
Cells of the muscle tissue, vascular endothelium, heart, and liver carry out the insulin-dependent cascade. The response generated by insulin’s effects in these cells is tissue-specific. In adipose tissue, skeletal muscle, and the heart, the result is glucose metabolism via glucose uptake into cells. Vasodilation via the production of nitrous oxide (NO) is the result seen in the vascular endothelium and heart. The liver exhibits a decrease in gluconeogenesis and increases in glycogenesis in response to the presence of insulin. Insulin’s effect stretches to lipid and protein metabolism as well. It stimulates lipogenesis and protein synthesis and conversely inhibits lipolysis and protein degradation.
Insulin is a peptide hormone comprised of 51 amino acids distributed among two peptide chains, the A and B chains of 21 and 30 amino acid residues respectively. Disulfide bonds of cysteine residues connect the 2 chains. Preproinsulin is the original precursor protein of insulin. It is a single-chain polypeptide consisting of proinsulin and signal peptide sequence. Upon its translocation into the endoplasmic reticulum, preproinsulin is cleaved at its signal peptide, releasing proinsulin. Proinsulin is a single-chain containing insulin’s A and B chains in a continuous fashion joined through a segment known as the C domain. Dibasic residues flank the C domain at each end. At the site of each dibasic residue, a trypsin-like enzyme cleaves proinsulin. This cleavage finally releases insulin along with a C-peptide. Until it is metabolically needed, insulin is stored within glucose-regulated secretory vesicles as zinc insulin hexamers.
Role in Glucose Metabolism
The homeostasis of glucose metabolism is carried out by 2 signaling cascades: insulin-mediated glucose uptake (IMGU) and glucose-stimulated insulin secretion (GSIS). The IMGU cascade allows insulin to increase the uptake of glucose from skeletal muscle and adipose tissue, as well as suppress glucose generation by hepatic cells. Activation of the insulin cascade’s downstream signaling begins when insulin extracellularly interacts with the insulin receptor’s alpha subunit. This interaction leads to conformational changes in the insulin-receptor complex, eventually leading to tyrosine kinase phosphorylation of insulin receptor substrates and subsequent activation of phosphatidylinositol-3-kinase. These downstream events cause the desired translocation of the GLUT-4 transporter from intracellular to extracellular onto skeletal muscle cell’s plasma membrane. Intracellularly, GLUT4 is present within vesicles. The rate at which these GLUT4-vesicles are exocytosed increases due to insulin’s actions or exercise. Thus, by increasing GLUT-4’s presence on the plasma membrane, insulin allows for glucose entry into skeletal muscle cells for metabolism into glycogen.
Role in Glycogen Metabolism
In the liver, insulin effects glycogen metabolism by stimulation of glycogen synthesis. Protein phosphatase I (PPI) is the key molecule in the regulation of glycogen metabolism. Via dephosphorylation, PPI slows the rate of glycogenolysis by inactivating phosphorylase kinase and phosphorylase A. In contrast, PPI accelerates glycogenesis by activating glycogen synthase B. Insulin serves to increase PPI substrate-specific activity on glycogen particles, in turn, stimulating the synthesis of glycogen from glucose in the liver.
There are a variety of hepatic metabolic enzymes under the direct control of insulin through gene transcription. This effects gene expression in metabolic pathways. In gluconeogenesis, insulin inhibits gene expression of the rate-limiting step, phosphoenolpyruvate carboxylase, as well as fructose-1,6-bisphosphatase and glucose-6-phosphatase. In glycolysis, gene expression of glucokinase and pyruvate kinase increases. In lipogenesis, the expression is increased of fatty acid synthase, pyruvate dehydrogenase, and acetyl-CoA carboxylase.
Role in Lipid Metabolism
As previously mentioned, insulin increases the expression of some lipogenic enzymes. This is due to glucose stored as a lipid within adipocytes. Thus, an increase in fatty acid generation will increase glucose uptake by the cells. Insulin further regulates this process by dephosphorylating and subsequently inhibiting hormone-sensitive lipase, leading to inhibition of lipolysis. Ultimately, insulin decreases serum free fatty acid levels.
Role in Protein Metabolism
Protein turnover rate is regulated in part by insulin. Protein synthesis is stimulated by insulin’s increase in intracellular uptake of alanine, arginine, and glutamine (short chain amino acids), as well as gene expression of albumin and muscle myosin heavy chain alpha. Regulation of protein breakdown is affected by insulin’s downregulation of hepatic and muscle cell enzymes responsible for protein degradation. The impacted enzymes include ATP-ubiquitin-dependent proteases, and ATP-independent lysosomal proteases and hydrolases.
Role in Inflammation and Vasodilation
Insulin’s actions within endothelial cells and macrophages have an anti-inflammatory effect on the body. Within endothelial cells, insulin stimulates the expression of endothelial nitric oxide synthase (eNOS). eNOS functions to release nitric oxide (NO), which leads to vasodilation. Insulin suppresses nuclear factor-kappa-B (NF-kB) found intracellularly in endothelial cells. Endothelial NF-KB activates expression of adhesion molecules, E-selectin, and ICAM-1, which release soluble cell adhesion molecules into the circulation. Studies have linked the presence of cell adhesion molecules on vascular endothelium to the development of atherosclerotic arterial plaques.
Insulin suppresses the generation of O2 radicals and reactive oxygen species (ROS). Within the macrophage, insulin inhibits expression of NADPH oxidase by suppressing one of its key components, p47phox. NADPH oxidase aids in the generation of oxygen radicals, which activate the inhibitor of NF-kB kinase beta (IKKB). IKKB phosphorylates IkB, leading to its degradation. This degradation releases NF-kB, allowing for its translocation in the macrophage’s nucleus. Once in the nucleus, NF-kB stimulates gene transcription of pro-inflammatory proteins which are released into the circulation, such as: inducible nitric oxide synthase (iNOS), tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), interleukin-8 (IL-8), monocyte chemoattractant protein (MCP-1), and matrix metalloproteinase (MMP).
There is a group of metabolic diseases in which the body experiences chronic hyperglycemia. Type 1, insulin-dependent, diabetes mellitus is a condition in which the pancreas has low or absent production of insulin. Type 2, insulin-independent, diabetes mellitus (DM) is a condition in which the body produces insulin, but it is not enough to effectively keep up with the body’s glucose metabolic demands. This supply and demand mismatch leads to insulin resistance and abnormal glucose metabolism. In both type 1 and type 2 DM, glucose remains at an elevated level in the bloodstream because its proper transport into cells and metabolism are not occurring normally. Type 2 DM has reached epidemic standards within the United States. This is of significant concern due to the vast complications caused by DM. These include neuropathy, renal failure, retinopathy, cardiovascular disease, and peripheral vascular disease.
During the early stage of type 2 DM development, although the body experiences high levels of blood glucose, the pancreatic beta cells produce enough insulin to maintain euglycemia. Insulin production becomes ineffective for adequate glucose metabolism when part of the insulin-mediated glucose uptake cascade is dysfunctional. Specifically, glucose transport across the plasma membrane via GLUT-4 transporters becomes impaired causing insulin resistance to glycogenesis in muscle cells. GLUT-4 transporter impairment may occur either due to persistent hyperglycemia or may have been inherently present.
|||Zhao L,Wang L,Zhang Y,Xiao S,Bi F,Zhao J,Gai G,Ding J, Glucose Oxidase-Based Glucose-Sensitive Drug Delivery for Diabetes Treatment. Polymers. 2017 Jun 29; [PubMed PMID: 30970930]|
|||Najjar SM,Perdomo G, Hepatic Insulin Clearance: Mechanism and Physiology. Physiology (Bethesda, Md.). 2019 May 1; [PubMed PMID: 30968756]|
|||Slater T,Haywood NJ,Matthews C,Cheema H,Wheatcroft SB, Insulin-like growth factor binding proteins and angiogenesis: from cancer to cardiovascular disease. Cytokine [PubMed PMID: 30954375]|
|||Daghlas SA,Mohiuddin SS, Biochemistry, Glycogen 2019 Jan; [PubMed PMID: 30969624]|
|||Rinaldi G,Hijazi A,Haghparast-Bidgoli H, Cost and cost-effectiveness of mHealth interventions for the prevention and control of type 2 diabetes mellitus: a protocol for a systematic review. BMJ open. 2019 Apr 11; [PubMed PMID: 30975686]|
|||Giugliano D,De Nicola L,Maiorino MI,Bellastella G,Esposito K, Type 2 diabetes and the kidney: insights from cardiovascular outcome trials. Diabetes, obesity [PubMed PMID: 30969018]|
|||Demircik F,Kirsch V,Ramljak S,Vogg M,Pfützner AH,Pfützner A, Laboratory Evaluation of Linearity, Repeatability, and Hematocrit Interference With an Internet-Enabled Blood Glucose Meter. Journal of diabetes science and technology. 2019 Apr 11; [PubMed PMID: 30974988]|
|||Eleftheriadou I,Tentolouris A,Tentolouris N,Papanas N, Advancing pharmacotherapy for diabetic foot ulcers. Expert opinion on pharmacotherapy. 2019 Apr 8; [PubMed PMID: 30958725]|
|||Kuzulugil D,Papeix G,Luu J,Kerridge RK, Recent advances in diabetes treatments and their perioperative implications. Current opinion in anaesthesiology. 2019 Apr 2; [PubMed PMID: 30958402]|
|||Athyros VG,Polyzos SA,Kountouras J,Katsiki N,Anagnostis P,Doumas M,Mantzoros CS, Non-alcoholic fatty liver disease treatment in patients with type 2 diabetes mellitus; new kids on the block. Current vascular pharmacology. 2019 Apr 5; [PubMed PMID: 30961499]|
|||Papamichou D,Panagiotakos DB,Itsiopoulos C, Dietary patterns and management of type 2 diabetes: A systematic review of randomised clinical trials. Nutrition, metabolism, and cardiovascular diseases : NMCD. 2019 Feb 25; [PubMed PMID: 30952576]|